Weekly chemoradiation (docetaxel/cisplatin) followed by surgery in stage III NSCLC; a multicentre phase II study

Anticancer Research

Volumn 30, Issue 10, 2010, Pages 4237-4243

  Maas, Klaartje W ^a   El Sharouni, Sherif Y ^b   Phernambucq, Erik C J ^c   Stigt, Jos A ^d   Groen, Harry J M ^e   Herder, Gerarda J M ^c   Van Den Borne, Ben E E M ^f   Senan, Suresh ^c   Paul, Marinus A ^c   Smit, Egbert F ^c   Schramel, Franz M N H ^a  

^a ST ANTONIUS HOSPITAL   (Netherlands)

^b UNIVERSITY MEDICAL CENTER UTRECHT   (Netherlands)

^c VU UNIVERSITY MEDICAL CENTER   (Netherlands)

^d ISALA HOSPITAL   (Netherlands)

^e UNIVERSITY MEDICAL CENTER GRONINGEN   (Netherlands)

^f CATHARINA HOSPITAL   (Netherlands)

Author keywords

Chemoradiation; Cisplatin; Non small cell lung cancer; Pneumonectomy; Stage III; Surgery

Indexed keywords

CISPLATIN; DOCETAXEL;

ADULT; ADULT RESPIRATORY DISTRESS SYNDROME; AGED; ARTICLE; ATELECTASIS; CANCER CHEMOTHERAPY; CANCER MORTALITY; CANCER RADIOTHERAPY; CANCER STAGING; CANCER SURGERY; CANCER SURVIVAL; CLINICAL ARTICLE; CLINICAL TRIAL; DISEASE COURSE; DRUG EFFICACY; EMPYEMA; ESOPHAGITIS; FEASIBILITY STUDY; FEMALE; HUMAN; HYPOVOLEMIC SHOCK; LOBECTOMY; LUNG NON SMALL CELL CANCER; LUNG RESECTION; MALE; MORBIDITY; MULTIPLE CYCLE TREATMENT; OVERALL SURVIVAL; PHASE 2 CLINICAL TRIAL; PNEUMONIA; POSTOPERATIVE PERIOD; PRIORITY JOURNAL; PROSPECTIVE STUDY; RADIATION DOSE FRACTIONATION; RADIATION PNEUMONIA; RASH; STOMACH HEMORRHAGE; SUBCUTANEOUS EMPHYSEMA; SUBCUTANEOUS HEMORRHAGE; SURGICAL MORTALITY; THORACOTOMY; TREATMENT RESPONSE; UPPER RESPIRATORY TRACT INFECTION; WOUND DEHISCENCE;

ADULT; AGED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CARCINOMA, NON-SMALL-CELL LUNG; CISPLATIN; COMBINED MODALITY THERAPY; DRUG ADMINISTRATION SCHEDULE; FEMALE; HUMANS; LUNG NEOPLASMS; MALE; MIDDLE AGED; NEOPLASM STAGING; RADIOTHERAPY; SURVIVAL RATE; TAXOIDS;

EID: 78650247801     PISSN: 02507005     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (33)

1. Pfister DG, Johnson DH and Azzoli CG: American Society of Clinical Oncology. Treatment of Unresectable Non-Small Cell Lung Cancer Guideline: update 2003. J Clin Oncol 22: 330-353, 2004.
2. Albain KS, Swann RS and Rush VW: Radiotherapy plus chemotherapy with or without surgical resection for stage III non-small cell lung cancer: a phase III randomised controlled trial. Lancet 374: 379-386, 2009.
3. Van Meerbeeck JP, Kramer GWPM and van Schil PEY: Randomized controlled trial of resection versus radiotherapy after induction chemotherapy in stage IIIA-N2 non-small cell lung cancer. J Natl Cancer Inst 99: 442-450, 2007.
4. Thomas M, Rube C and Hoffknecht P: Effect of preoperative chemoradiation in addition to preoperative chemotherapy: a randomised trial in stage III non-small cell lung cancer. Lancet Oncol 9: 636-648, 2008.
5. Choy H, Rodriquez FF and Koester S: Investigation of taxol as a potential radioation sensitizer. Cancer 71: 3774-3778, 1993.
6. Choy H and Browne MJ: Paclitaxel as a radiation sensitizer in non-small cell lung cancer. Semin Oncol 22(3 suppl 6): 70-74, 1995.
7. McGuire WP, Rowinsky EK and Rosenshein NB: Taxol: a unique antineoplastic agent with significant activity ina advanced ovarian epitheralial neoplasms. Ann Int Med 111: 273-279, 1989.
8. Amarino GP, Hamilton VM and Choy H: Enhancement of radioation effects by combined cisplatin and carboplatin treatment in vitro. Radiat Oncol Invest 7(6): 343-352, 1999.
9. Mason K, Staab A and Hunter N: Enhancement of tumor radioresponse by docetaxel: involvement of immune system. Int J Oncol 18: 599-606, 2001.
10. Dicker AP, Williams T and Lliakis G: Inhibition of angiogenic processes in endotheralial cells by docetaxel (taxotere) and paclitaxel (taxol) induced radiosensitization: a potential anti-angiogenic strategy. Am Soc Ther Rad Oncol 42: abstract, 2002.
11. Tomiak E, Piccart MJ and Kerger J: Phase I study of docetaxel administered as a 1-hour intravenous infusion on a weekly basis. J Clin Oncol 12(7): 1458-1467, 1994.
12. Mudad R, Ramsey M and Kovitz K: Concomitant weekly docetaxel, cisplatin and radiation therapy in locally advanced non-small cell lung cancer: a dose-finding study. Lung Cancer 39(2): 173-177, 2003.
13. Mauer AM, Masters GA and Hara DJ: Phase I study of docetaxel with concomitant thoracic radiation therapy. J Clin Oncol 16: 159-164, 1998.
14. Koukourakis MI, Kourousis C and Kamilaki M: Weekly docetaxel and concomitant boost radiotherapy for non-small cell lung cancer. A phase I/II dose escalation trial. Eur J Cancer 34: 838-844, 1998.
15. Koukourakis MI, Bahlitzanakis N and Froudarakis M: Concurrent conventionally fractionated radiotherapy and weekly docetaxel in the treatment of stage IIIB non-small cell lung carcinoma. Br J Cancer 80: 1792-1796, 1999.
16. Choy H, DeVore RF and Hande KR: Phase I trial of outpatient weekly docetaxel, carboplatin and concurrent thoracic radiation therapy for stage III unresectable non-small cell lung cancer: a Vanderbilt cancer center affiliate network (VCCAN) trial. Lung Cancer 34: 441-449, 2001.
17. Segawa Y, Ueoka H and Kiura K: A phase I/II study of docetaxel (TXT) and cisplatin (CDDP) with concurrent thoracic radiotherapy (TRT) for locally advanced non-small cell lung cancer (NSCLC). Proc Am Soc Clin Oncol 19: 508a (abstract), 2000.
18. Sato K, Tsuchiya S and Minato K: A phase I trial of weekly docetaxel and cisplatin in advanced non-small cell lung cancer. Lung cancer 33: 69-73, 2001.
19. Moriyama A, Komiya K and Yamamoto N: A phase I trial of weekly docetaxel (DXT) and cisplatin (CDDP) concomitant with thoracic radiotherapy (TRT) for patients with unresectable locally advanced non-small cell lung cancer (NSCLC). Ann Oncol 11(Suppl 4): 110 (abstract), 2000.
20. Wu HG, Bang YJ and Choi EK: Phase I study of weekly docetaxel and cisplatin concurrent with radiotherapy in stage III non-small cell lung cancer. Int J Radiat Oncol Biol Phys 52: 75-80, 2002.
21. Diagnosis and Management of lung Cancer: ACCP Evidence-Based Clinical Practice Guidelines (2nd Edition) 132: supplement 3, 2007.
22. Senan S, De ruysscher D and Giraud: Literature-based recommendations for treatment planning and execution in high-dose radiotherapy for lung cancer. Radiother Oncol 71: 139-146, 2004.
23. Naruke T, Suemasu K and Ishikawa S: Lymph node mapping and curability at various levels of metastasis in resected lung cancer. J Thorac Cardiovasc Surg 76(6): 832-839, 1978.
24. Rami-Porta R, Wittekind C and Goldstraw P: Complete resection in lung cancer surgery: proposed definition. Lung Cancer 49: 25-33, 2005.
25. Kaplan EL and Meier P: Non-parametric estimations from incomplete observation. J Am Stat Assoc 53: 457-481, 1958.
26. Peto R and Peto J: Asymptotically efficient rank invariant test procedures. J R Stat Soc (series A) 135: 185-198, 1972.
27. Katayama H, Ueoka H and Kiura K: Preoperative concurrent chemoradiotherapy with cisplatin and docetaxel in patients with locally advanced non-small cell lung cancer. Br J Cancer 90: 979-984, 2004.
28. Farray D, Mirkovic N and Albain KS: Multimodality therapy for stage IH non-small cell lung cancer. J Clin Oncol 23: 3257-3269, 2005.
29. Betticher DC, Schimtz SFH and Totsch M: Mediastinal lymph node clearance after docetaxel-cisplatin neoadjuvant chemotherapy is prognostic of surival in patients with stage IIIA pN2 non-small cell lung cancer: a multicenter phase II trial. J Clin Oncol 21: 1752-1759, 2003.
30. Martin J, Ginsberg RJ and Venkatraman ES: Long-term results of combined-modality therapy in respectable non-small cell lung cancer. J Clin Oncol 20: 1989-1995, 1995.
31. Albain KS, Rush VW and Crawly JJ: Concurrent cisplatin/etoposide plus chest radiotherapy followed by surgery for stages IIIA (N2) and IIIB non-small cell lung cancer: Mature results of South-west Oncology Group Phase II study 8805. J Clin Oncol 13: 1880-1892, 1995.
32. Cerfolio RJ, Bryant AS and Jones VL: Pulmonary resection after concurrent chemotherapy and high dose (60Gy) radiation for non-small cell lung cancer is safe and may provide increased survival. Eur J Cardiothorac Surg 35(4): 718-723, 2009.
33. Hanna NH, Neubauer M and Ansari R: Phase III trial of cisplatin (P)/etoposide (E) and concurrent chest radiation (XRT) with or without consolidation docetaxel (D) in patients (pts) with inoperable stage III non-small cell lung cancer (NSCLC): HOG LUN 01-24/USO-023. J Clin Oncol 25: 7512, 2007.